Development of neoantigens: from identification in cancer cells to application in cancer vaccines

References

• Havrilov A, Trehub Y. Oncolytic viruses as immunotherapeutic agents. Tehran, Iran: Tehran University of Medical Sciences; 2020.
   Google Scholar
• Coulie P, Van den Eynde B, van der Bruggen P, et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135–146.
   PubMed Web of Science ®Google Scholar
• Bobisse S, Foukas PG, Coukos G, et al. Neoantigen-based cancer immunotherapy. Ann Transl Med. 2016;4(14):262.
   PubMed Web of Science ®Google Scholar
• Ward JP, Gubin MM, Schreiber RD. The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer. Adv Immunol. 2016;130:25–74.
   PubMed Web of Science ®Google Scholar
• Topper MJ, Vaz M, Marrone KA, et al. The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2020;17(2):75–90.
   PubMed Web of Science ®Google Scholar
• Efremova M, Finotello F. Rieder D and Trajanoski Z, Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. Front Immunol. 2017;8:1679.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725–741.
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy–revisited. Nat Rev Drug Discov. 2011;10(8):591–600.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Prada N, Kepp O, et al. Current trends of anticancer immunochemotherapy. Milton Park, UK: Taylor & Francis; 2013.
   Google Scholar
• Garg NK, Dwivedi P, Prabha P, et al. RNA pulsed dendritic cells: an approach for cancer immunotherapy. Vaccine. 2013;31(8):1141–1156.
   PubMed Web of Science ®Google Scholar
• Li Q, Ding Z-Y. The ways of isolating neoantigen-specific T cells. Front Oncol. 2020;10:1347.
   PubMed Web of Science ®Google Scholar
• Rohaan MW, Wilgenhof S, Haanen JB. Adoptive cellular therapies: the current landscape. Virchows Arch. 2019;474(4):449–461.
   PubMed Web of Science ®Google Scholar
• Alatrash G, Crain AK, Molldrem JJ. Tumor-associated antigens, in Immune biology of allogeneic hematopoietic stem cell transplantation. - 2019, Cambridge, MA, USA: Elsevier; p. -143-164.
   Google Scholar
• Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4(1):1–10.
   PubMedGoogle Scholar
• Wang R-F. Tumor antigens discovery: perspectives for cancer therapy. Mol Med. 1997;3(11):716–731.
   PubMed Web of Science ®Google Scholar
• De S, Lurquin C, van der Bruggen C, et al. Sequence and expression pattern of the human MAGE2 gene. Immunogenetics. 1994;39(2):121–129.
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Ritter E, Büchler WM, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci. 2010;107(11):5088–5093.
   PubMed Web of Science ®Google Scholar
• Hofmann O, Caballero O, Stevenson B, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci. 2008;105(51):20422–20427.
   PubMed Web of Science ®Google Scholar
• Simpson A, Caballero O, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615–625.
   PubMed Web of Science ®Google Scholar
• Bakker A, Schreurs M, De Boer AJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994;179(3):1005–1009.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci. 1994;91(9):3515–3519.
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Fitzgerald EB, Southwood S, et al. Identification of a shared HLA-A* 0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 1998;58(21):4895–4901.
   PubMed Web of Science ®Google Scholar
• Correale P, Nieroda C, Zaremba S, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst. 1997;89(4):293–300.
   PubMedGoogle Scholar
• Lam K-W, Li C-Y, Yam LT, et al. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate. 1989;15(1):13–21.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Hahn WC, Schultze JL, et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10(6):673–679.
   PubMed Web of Science ®Google Scholar
• Disis ML, Wallace DR, Gooley TA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009;27(28):4685.
   PubMed Web of Science ®Google Scholar
• Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci. 1996;93(1):136–140.
   PubMed Web of Science ®Google Scholar
• Finn OJ, Gantt KR, Lepisto AJ, et al. Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunol Res. 2011;50(2–3):261–268.
   PubMed Web of Science ®Google Scholar
• Lee C-M, Lu S-N, Changchien C-S, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer. 1999;86(7):1143–1150.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–314.
   PubMed Web of Science ®Google Scholar
• Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(1):59–68.
   PubMed Web of Science ®Google Scholar
• Ghanaat M, Goradel NH, Arashkia A, et al. Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer. Acta Pharmacol Sin. 2021; DOI:10.1038/s41401-021-00616-5.
   PubMed Web of Science ®Google Scholar
• Bräunlein E, Krackhardt AM. Identification and characterization of neoantigens as well as respective immune responses in cancer patients. Front Immunol. 2017;8:1702.
   PubMed Web of Science ®Google Scholar
• Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514):324–327.
   PubMed Web of Science ®Google Scholar
• Wang R-F, Wang HY. Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res. 2017;27(1):11–37.
   PubMed Web of Science ®Google Scholar
• Tang S, Madhavan S. neoantigen R: an annotation based pipeline for tumor neoantigen identification from sequencing data. bioRxiv. 2017;171843. DOI: 10.1101/171843.
   Google Scholar
• Tappeiner E, Finotello F, Charoentong P, et al. TIminer: NGS data mining pipeline for cancer immunology and immunotherapy. Bioinformatics. 2017;33(19):3140–3141.
   PubMed Web of Science ®Google Scholar
• Hundal J, Carreno BM, Petti AA, et al. pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 2016;8(1):1–11.
   PubMedGoogle Scholar
• Javidi MA, Ahmadi AH, Bakhshinejad B, et al. Cell-free microRNAs as cancer biomarkers: the odyssey of miRNAs through body fluids. Med Oncol. 2014;31(12):295.
   PubMed Web of Science ®Google Scholar
• Bassani-Sternberg M, Bräunlein E, Klar R, et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun. 2016;7(1):1–16.
   Google Scholar
• Bassani-Sternberg M. Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens. Methods Mol Biol. 2018;1719:209-221. DOI:10.1007/978-1-4939-7537-2_14
   Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199.
   PubMed Web of Science ®Google Scholar
• Gros A, Garcia-Garijo A, Fajardo CA. Determinants for neoantigen identification. Front Immunol. 2019;10:1392.
   PubMed Web of Science ®Google Scholar
• Finlay BB, McFadden G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell. 2006;124(4):767–782.
   PubMed Web of Science ®Google Scholar
• Kuroki M, Ueno A, Matsumoto H, et al. Significance of tumor-associated antigens in the diagnosis and therapy of cancer: an overview. Anticancer Res. 2002;22(6C):4255–4264.
   PubMed Web of Science ®Google Scholar
• Wolfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995;269(5228):1281–1284.
   PubMed Web of Science ®Google Scholar
• Coulie PG, Lehmann F, Lethe B, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci. 1995;92(17):7976–7980.
   PubMed Web of Science ®Google Scholar
• Brändle D, Brasseur F, Weynants P, et al. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med. 1996;183(6):2501–2508.
   PubMed Web of Science ®Google Scholar
• Hogan KT, Eisinger DP, Cupp SB, et al. The peptide recognized by HLA-A68. 2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res. 1998;58(22):5144–5150.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhao W, Zhou B, et al. TSNAdb: a database for tumor-specific neoantigens from immunogenomics data analysis. Genomics Proteomics Bioinformatics. 2018;16(4):276–282.
   PubMed Web of Science ®Google Scholar
• Arnaud M, Duchamp M, Bobisse S, et al. Biotechnologies to tackle the challenge of neoantigen identification. Curr Opin Biotechnol. 2020;65:52–59.
   PubMed Web of Science ®Google Scholar
• Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400–404.
   PubMed Web of Science ®Google Scholar
• Roudko V, Greenbaum B, Bhardwaj N. Computational prediction and validation of tumor-associated neoantigens. Front Immunol. 2020;11:27.
   PubMed Web of Science ®Google Scholar
• Saini SK, Rekers N, Hadrup SR. Novel tools to assist neoepitope targeting in personalized cancer immunotherapy. Ann Oncol. 2017;28:xii3–xii10.
   PubMed Web of Science ®Google Scholar
• Orentas RJ, Nordlund J, He J, et al. Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison. Front Oncol. 2014;4:134.
   PubMedGoogle Scholar
• Hammerbacher J, Snyder A. Informatics for cancer immunotherapy. Ann Oncol. 2017;28:xii56–xii73.
   PubMedGoogle Scholar
• Linnemann C, Van Buuren MM, Bies L, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nature Med. 2015;21(1):81–85.
   PubMed Web of Science ®Google Scholar
• Amirmahani F, Ebrahimi N, Molaei F, et al. Approaches for the integration of big data in translational medicine: single-cell and computational methods. Ann N Y Acad Sci.
   Web of Science ®Google Scholar
• Li K, Vaudel M, Zhang B, et al. PDV: an integrative proteomics data viewer. Bioinformatics. 2019;35(7):1249–1251.
   PubMed Web of Science ®Google Scholar
• Wen B, Li K, Zhang Y, et al. Cancer neoantigen prioritization through sensitive and reliable proteogenomics analysis. Nat Commun. 2020;11(1):1–14.
   PubMed Web of Science ®Google Scholar
• Lancaster EM, Jablons D, Kratz JR. Applications of next-generation sequencing in neoantigen prediction and cancer vaccine development. Genet. Test. Mol. Biomark. 2020;24(2):59–66.
   PubMed Web of Science ®Google Scholar
• McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–1303.
   PubMed Web of Science ®Google Scholar
• Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568–576.
   PubMed Web of Science ®Google Scholar
• Hackl H, Charoentong P, Finotello F, et al. Computational genomics tools for dissecting tumour–immune cell interactions. Nat Rev Genet. 2016;17(8):441.
   PubMed Web of Science ®Google Scholar
• Szolek A, Schubert B, Mohr C, et al. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 2014;30(23):3310–3316.
   PubMed Web of Science ®Google Scholar
• Shukla SA, Rooney MS, Rajasagi M, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015;33(11):1152–1158.
   PubMed Web of Science ®Google Scholar
• Boegel S, Löwer M, Schäfer M, et al. HLA typing from RNA-Seq sequence reads. Genome Med. 2013;4(12):1–12.
   Google Scholar
• Warren RL, Choe G, Freeman DJ, et al. Derivation of HLA types from shotgun sequence datasets. Genome Med. 2012;4(12):1–8.
   PubMedGoogle Scholar
• Lundegaard C, Lamberth K, Harndahl M, et al. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11. Nucleic Acids Res. 2008;36(suppl_2):W509–W512.
   PubMedGoogle Scholar
• Nielsen M, Andreatta M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med. 2016;8(1):1–9.
   PubMedGoogle Scholar
• Bjerregaard A-M, Nielsen M, Hadrup SR, et al. MuPeXI: prediction of neo-epitopes from tumor sequencing data. Cancer Immunol Immunother. 2017;66(9):1123–1130.
   PubMed Web of Science ®Google Scholar
• Wick DA, Webb JR, Nielsen JS, et al. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res. 2014;20(5):1125–1134.
   PubMed Web of Science ®Google Scholar
• Melero I, Gaudernack G, Gerritsen W, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11(9):509.
   PubMed Web of Science ®Google Scholar
• Li L, Goedegebuure S, Gillanders WE. Preclinical and clinical development of neoantigen vaccines. Ann Oncol. 2017;28:xii11–xii17.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74.
   PubMed Web of Science ®Google Scholar
• Kuai R, Ochyl LJ, Bahjat KS, et al. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 2017;16(4):489–496.
   PubMed Web of Science ®Google Scholar
• Fang Y, Mo F, Shou J, et al. A pan-cancer clinical study of personalized neoantigen vaccine monotherapy in treating patients with various types of advanced solid tumors. Clin Cancer Res. 2020;26(17):4511–4520.
   PubMed Web of Science ®Google Scholar
• Yadav M, Jhunjhunwala S, Phung QT, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515(7528):572–576.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687–692.
   PubMed Web of Science ®Google Scholar
• Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168.
   PubMed Web of Science ®Google Scholar
• Moy JD, Moskovitz JM, Ferris RL. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. Eur J Cancer. 2017;76:152–166.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–221.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–226.
   PubMed Web of Science ®Google Scholar
• Keskin DB, Anandappa AJ, Sun J, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234–239.
   PubMed Web of Science ®Google Scholar
• Hilf N, Kuttruff-Coqui S, Frenzel K, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240–245.
   PubMed Web of Science ®Google Scholar
• Bhatt D, Daemen T, Vaccines T, et al., 2020, Multidisciplinary digital publishing institute.
   Google Scholar
• Garg AD, Galluzzi L, Apetoh L, et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 2015;6:588.
   PubMed Web of Science ®Google Scholar
• Jiang T, Shi T, Zhang H, et al. Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol. 2019;12(1):1–13.
   PubMed Web of Science ®Google Scholar
• Mondal M, Guo J, He P, et al. Recent advances of oncolytic virus in cancer therapy. Hum Vaccines Immunother. 2020;16(10):2389–2402.
   PubMed Web of Science ®Google Scholar
• Guo C, Manjili MH, Subjeck JR, et al. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013;119:421–475.
   PubMed Web of Science ®Google Scholar
• Stratford R, Douce G, Zhang-Barber L, et al. Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus. Vaccine. 2000;19(7–8):810–815.
   PubMed Web of Science ®Google Scholar
• Lin EY, Li J-F, Gnatovskiy L, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006;66(23):11238–11246.
   PubMed Web of Science ®Google Scholar
• Ribas A, Weber JS, Chmielowski B, et al. Intra–lymph node prime-boost vaccination against melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial. Clin Cancer Res. 2011;17(9):2987–2996.
   PubMed Web of Science ®Google Scholar
• Weber JS, Vogelzang NJ, Ernstoff MS, et al. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother. 2011;34(7):556. Hagerstown, Md: 1997.
   PubMed Web of Science ®Google Scholar
• Duperret EK, Perales-Puchalt A, Stoltz R, et al. A synthetic DNA, multi-neoantigen vaccine drives predominately MHC class I CD8+ T-cell responses, impacting tumor challenge. Cancer Immunol Res. 2019;7(2):174–182.
   PubMed Web of Science ®Google Scholar
• Scheel B, Teufel R, Probst J, et al. Toll‐like receptor‐dependent activation of several human blood cell types by protamine‐condensed mRNA. Eur J Immunol. 2005;35(5):1557–1566.
   PubMed Web of Science ®Google Scholar
• Carralot J-P, Probst J, Hoerr I, et al. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci. 2004;61(18):2418–2424.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Brest P, Refae S, Mograbi B, et al. Host polymorphisms may impact SARS-CoV-2 infectivity. Trends Genet. 2020;36(11):813–815.
   PubMed Web of Science ®Google Scholar
• Gosain R, Abdou Y, Singh A, et al. COVID-19 and cancer: a comprehensive review. Curr Oncol Rep. 2020;22(5):1–15.
   PubMed Web of Science ®Google Scholar
• Fanciullino R, Ciccolini J, Milano G. COVID-19 vaccine race: watch your step for cancer patients. Br J Cancer. 2021;124(5):860–861.
   PubMed Web of Science ®Google Scholar
• Bonehill A, Van Nuffel AM, Corthals J, et al. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res. 2009;15(10):3366–3375.
   PubMed Web of Science ®Google Scholar
• Jäger E, Gnjatic S, Nagata Y, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci. 2000;97(22):12198–12203.
   PubMed Web of Science ®Google Scholar
• Ménager J, Ebstein F, Oger R, et al. Cross-presentation of synthetic long peptides by human dendritic cells: a process dependent on ERAD component p97/VCP but Not sec61 and/or Derlin-1. PLoS One. 2014;9(2):e89897.
   PubMed Web of Science ®Google Scholar
• Schuette V, Burgdorf S. The ins-and-outs of endosomal antigens for cross-presentation. Curr Opin Immunol. 2014;26:63–68.
   PubMed Web of Science ®Google Scholar
• Ho NI, Huis in ‘t Veld LGM, Raaijmakers TK, et al. Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines? Front Immunol. 2018;9:2874.
   PubMed Web of Science ®Google Scholar
• Cai A, Keskin DB, DeLuca DS, et al. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin Cancer Res. 2012;18(20):5761–5772.
   PubMed Web of Science ®Google Scholar
• Chen F, Zou Z, Du J, et al. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Investig. 2019;129(5):2056–2070.
   PubMed Web of Science ®Google Scholar
• Hutchison S, Pritchard AL. Identifying neoantigens for use in immunotherapy. Mamm. Genome. 2018;29(11–12):714–730.
   PubMed Web of Science ®Google Scholar
• Saxena M, Bhardwaj N. Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer. 2018;4(2):119–137.
   PubMed Web of Science ®Google Scholar
• Garg AD, Vara Perez M, Schaaf M, et al. Trial watch: dendritic cell-based anticancer immunotherapy. Oncoimmunology. 2017;6(7):e1328341.
   PubMed Web of Science ®Google Scholar
• García-Vallejo JJ, Unger WW, Kalay H, et al. Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines. Oncoimmunology. 2013;2(2):e23040.
   PubMed Web of Science ®Google Scholar
• Carreno BM, Magrini V, Becker-Hapak M, et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348(6236):803–808.
   PubMed Web of Science ®Google Scholar
• Zhang X, Sharma PK, Goedegebuure SP, et al. Personalized cancer vaccines: targeting the cancer mutanome. Vaccine. 2017;35(7):1094–1100.
   PubMed Web of Science ®Google Scholar
• Walsh SR, Dolin R. Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines. 2011;10(8):1221–1240.
   PubMed Web of Science ®Google Scholar
• Madan RA, Bilusic M, Heery C, et al. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. In: Seminars in oncology.
   Google Scholar
• Woller N, Gürlevik E, Ureche C-I, et al. Oncolytic viruses as anticancer vaccines. Front Oncol. 2014;4:188.
   PubMedGoogle Scholar
• Aaes TL, Kaczmarek A, Delvaeye T, et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep. 2016;15(2):274–287.
   PubMed Web of Science ®Google Scholar
• Turubanova VD, Balalaeva IV, Mishchenko TA, et al. Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine. J Immunother Cancer. 2019;7(1):350.
   PubMed Web of Science ®Google Scholar
• Yatim N, Jusforgues-Saklani H, Orozco S, et al. RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8⁺ T cells. Science. 2015;350(6258):328–334.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. immunity. 2013;39(1):1–10.
   PubMed Web of Science ®Google Scholar
• Rezaei N, Keshavarz-Fathi M, Vaccines for cancer immunotherapy: an evidence-based review on current status and future perspectives. 2018.
   Google Scholar
• Song Q, Zhang C-D, Wu X-H. Therapeutic cancer vaccines: from initial findings to prospects. Immunol Lett. 2018;196:11–21.
   PubMed Web of Science ®Google Scholar
• Ali OA, Lewin SA, Dranoff G, et al. Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell activity and tumor eradication. Cancer Immunol Res. 2016;4(2):95–100.
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37–127ra37.
   PubMed Web of Science ®Google Scholar
• Chen L, Han X. Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–3391.
   PubMed Web of Science ®Google Scholar
• Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med. 2013;5(200):200ra116–200ra116.
   PubMed Web of Science ®Google Scholar
• Liu Y. Neoantigen: a long march toward cancer immunotherapy. Clin Cancer Res. 2016;22(11):2602–2604.
   PubMed Web of Science ®Google Scholar
• Eil R, Vodnala SK, Clever D, et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature. 2016;537(7621):539–543.
   PubMed Web of Science ®Google Scholar
• Mroz P, Szokalska A, Wu MX, et al. Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PloS One. 2010;5(12):e15194.
   PubMed Web of Science ®Google Scholar
• Gameiro SR, Jammed ML, Wattenberg MM, et al. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5(2):403.
   PubMed Web of Science ®Google Scholar
• Lugade AA, Moran JP, Gerber SA, et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174(12):7516–7523.
   PubMed Web of Science ®Google Scholar
• Machiels J-PH, Reillym RT, Emensm LA, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001;61(9):3689–3697.
   PubMed Web of Science ®Google Scholar
• Peng M, Mo Y, Wang Y, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18(1):1–14.
   PubMed Web of Science ®Google Scholar
• Aaes TL, Verschuere H, Kaczmarek A, et al. Immunodominant AH1 antigen-deficient necroptotic, but not apoptotic, murine cancer cells induce antitumor protection. J Immunol. 2020;204(4):775–787.
   PubMed Web of Science ®Google Scholar
• Goradel NH, Baker AT, Arashkia A, et al. Oncolytic virotherapy: challenges and solutions. Curr Probl Cancer. 2021;45(1):100639.
   PubMed Web of Science ®Google Scholar